Please find enclosed Annual Secretarial Compliance Report for the Financial Year ended March 31, 2026

Jagsonpal Pharmaceuticals Ltd has filed its Annual Secretarial Compliance Report for the financial year ended March 31, 2026, as required under SEBI Regulation 24A. The report, reviewed by Practicing Company Secretary Ayush Khandelwal & Associates, shows full compliance across all applicable SEBI regulations including LODR, Prohibition of Insider Trading, Takeover Regulations, Share Based Employee Benefits, and Secretarial Standards. The compliance table shows NIL deviations, NIL observations, and NIL fines across all 13 check points examined. No actions were taken against the company by SEBI or stock exchanges. Related party transactions were conducted with prior audit committee approval. No statutory auditor resignations occurred. All policies were adopted and updated on time.